PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin ® ), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

ConclusionAmong patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-EU in terms of efficacy. Safety profiles for the two treatments were comparable.Trial RegistrationClinicalTrials.gov, NCT02364999.FundingPfizer.

Source: BioDrugs - July 22, 2019 Category: Drugs & Pharmacology Source Type: research